Adaptogens for Stress and Anxiety: What They Can and Cannot Do

London, United Kingdom — 31 March 2026

Adaptogens are increasingly marketed for stress and anxiety — often interchangeably, as if these are the same condition. They are not. And the failure to distinguish between everyday stress and clinical anxiety disorders is one of the most significant responsible-marketing challenges facing the supplement industry. For B2B buyers and brand owners, understanding this distinction is not just an ethical imperative — it is a regulatory and legal one.

Stress and Anxiety Are Not the Same Thing

Stress is a normal physiological response to external demands — work deadlines, financial pressure, physical exertion. The body's stress-response system (the HPA axis) activates, cortisol rises, and when the stressor passes, the system returns to baseline. Chronic stress occurs when demands are sustained and the system remains persistently activated, leading to elevated cortisol, fatigue, sleep disruption, and reduced cognitive function. This is the domain where adaptogens have their strongest evidence base.

Anxiety, particularly generalised anxiety disorder (GAD), social anxiety, panic disorder, and other clinical presentations, involves a different and more complex neurobiology. While the HPA axis is involved, anxiety disorders also feature dysregulated amygdala activity, altered prefrontal cortex function, serotonergic and GABAergic imbalances, and often a genetic predisposition that is not addressable through supplementation alone. Clinical anxiety requires professional diagnosis and typically responds to cognitive behavioural therapy, pharmaceutical intervention, or both.

The distinction matters commercially because consumers searching for "anxiety supplements" may include individuals with undiagnosed clinical anxiety who need medical care, not a capsule. Brands that blur this line risk both regulatory action and genuine harm.

Ashwagandha: The Strongest Evidence for Stress Support

Ashwagandha is the adaptogen most associated with stress and anxiety outcomes in clinical literature. The evidence is genuinely meaningful — but it requires careful framing.

Multiple RCTs using KSM-66 (300 mg twice daily) and Sensoril (125–250 mg daily) have demonstrated statistically significant improvements on validated anxiety scales, including the Hamilton Anxiety Rating Scale (HAM-A) and the Perceived Stress Scale (PSS). The Chandrasekhar et al. (2012) study found a 27.9% reduction in serum cortisol and a 44% reduction in PSS scores compared to placebo. The Salve et al. (2019) study confirmed improvements in both stress and sleep quality metrics.

However, critical context is essential: these studies were conducted in adults with self-reported stress, not in populations diagnosed with clinical anxiety disorders. The participants were stressed professionals, not psychiatric patients. The improvements, while statistically significant, represent a shift from "moderately stressed" to "mildly stressed" — not a resolution of a clinical condition. This is a meaningful benefit, but it is support, not cure.

Rhodiola and Holy Basil: Complementary Evidence

Rhodiola rosea has demonstrated benefits for stress-related fatigue and burnout, with European clinical trials showing improvements in perceived stress and cognitive function under demanding conditions. Its mechanism (monoamine modulation) provides a different flavour of stress support from ashwagandha — more "mental resilience" than "calm." For consumers whose stress manifests as mental depletion rather than anxious tension, rhodiola may be the better-matched ingredient.

Holy basil (tulsi) has emerging evidence for anxiolytic and anti-stress effects, with a 2017 systematic review in the Journal of Ayurveda and Integrative Medicine concluding that tulsi demonstrated "favourable clinical effects" across multiple stress-related endpoints. However, the evidence base is smaller and less methodologically rigorous than ashwagandha's, consisting largely of open-label and smaller RCTs.

What Adaptogens Cannot Do

Adaptogens cannot treat clinical anxiety disorders. They cannot replace cognitive behavioural therapy. They cannot substitute for SSRIs, SNRIs, or other prescribed anxiolytics in individuals who need them. They cannot address the neurobiological complexity of panic disorder, PTSD, or severe generalised anxiety.

This is not a limitation unique to adaptogens — it applies to all dietary supplements. But adaptogens occupy a uniquely risky marketing position because the language of "stress and anxiety" so easily slides from the supplementable (chronic everyday stress) to the medical (clinical anxiety disorders). Every product claim, every social media post, every influencer partnership needs to maintain this boundary with precision.

Framing as Support, Not Cure

The responsible and commercially sustainable approach is to position adaptogens as one component of a broader stress-management strategy — alongside sleep hygiene, exercise, social connection, professional support when needed, and workload management. This framing is not weak marketing; it is honest marketing that builds long-term brand trust.

Effective messaging examples:

• "Supports your body's natural stress response" — defensible, accurate, aligned with clinical evidence.

• "May help maintain calm during demanding periods" — appropriately hedged, consumer-friendly.

• "Part of a balanced approach to stress management" — positions the product within a lifestyle context.

Problematic messaging examples:

• "Cures anxiety naturally" — medicinal claim, regulatory violation, potentially harmful.

• "The natural alternative to anti-anxiety medication" — implies pharmaceutical equivalence, encourages medication discontinuation.

• "Eliminates stress and anxiety" — absolute claim with no evidence basis.

Responsible Marketing: The Commercial Case

Beyond the ethical imperative, responsible marketing of adaptogens for stress has a strong commercial logic. The UK supplement market is experiencing a trust crisis, with consumer surveys consistently showing that fewer than 40% of adults trust supplement marketing claims. Brands that adopt transparent, evidence-based positioning — acknowledging what adaptogens can and cannot do — build disproportionate trust with the growing segment of informed, sceptical consumers who represent the highest lifetime value.

Conversely, brands making exaggerated anxiety claims face triple jeopardy: ASA complaint upholds that generate negative press, consumer disappointment when clinical anxiety is not resolved by a supplement, and potential MHRA action if claims cross into the medicinal territory.

What This Means for the United Kingdom

The UK regulatory framework draws a clear line between food supplement claims and medicinal claims. The ASA's CAP Code prohibits implied or direct claims that supplements can treat, cure, or prevent diseases — and clinical anxiety is classified as a medical condition. B2B suppliers have a direct role in supporting downstream compliance by providing claim guidance documents that distinguish between permissible stress-support claims and impermissible anxiety-treatment claims. Suppliers who include regulatory claim frameworks alongside their ingredient sales materials reduce their customers' compliance risk and strengthen commercial relationships. In a market where a single ASA ruling can damage a brand's reputation overnight, this guidance has quantifiable commercial value.

Contract-manufacturing partners such as Supplement Factory are increasingly central to bringing these formats to retail.